JMP Securities restated their market outperform rating on shares of Ariad Pharmaceuticals Inc (NASDAQ:ARIA) in a report released on Thursday, Analyst Ratings Net reports. JMP Securities currently has a $8.00 price objective on the stock, down from their previous price objective of $10.00. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) weekly performance is -7.75%. On last trading day company shares ended up $6.67. Analysts mean target price for the company is $9.06. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) distance from 50-day simple moving average (SMA50) is -13.20%.
Gilead Sciences, Inc. (NASDAQ:GILD) announced results from a Phase 1 clinical trial (GS-US-279-0110) of GS-6615, an investigational, selective late sodium current inhibitor, showing a shortening of the QTc interval (the time interval between the start of the Q-wave and end of the T-wave in the heart’s electrical cycle) in patients with long QT-3 (LQT3) syndrome. LQT3 is a genetic disorder that prolongs the heart’s QTc interval and can cause life-threatening cardiac arrhythmias (abnormal heartbeats). Gilead Sciences, Inc. (NASDAQ:GILD) shares advanced 1.31% in last trading session and ended the day on $79.76. Gross Margin is 77.80% and its return on assets is 19.10%. Gilead Sciences, Inc. (NASDAQ:GILD) quarterly performance is 1.28%.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) reported that Eisai plans to add more than 200 new contract sales representatives to its Metabolic Business Unit, increasing the sales force for BELVIQ® by 50% to approximately 600, triple the size from the commercial launch of BELVIQ in June 2013. Eisai expects this expansion of the sales force will become effective on July 1, 2014, and enable them to reach approximately 90,000 physicians in the United States. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares moved up 3.01% in last trading session and was closed at $7.19, while trading in range of $6.85 -$7.22 -. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) year to date (YTD) performance is 22.91%.
Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Chelsea Therapeutics International, Ltd (NASDAQ:CHTP) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by H. Lundbeck A/S (“Lundbeck”), in a transaction valued at approximately $658 million. Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) ended the last trading day at $6.57. Company weekly volatility is calculated as 4.04% and price to cash ratio as 11.41. Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) showed a positive weekly performance of 28.07%.